Filing Flows › Health Care › Repligen (RGEN)
Repligen (RGEN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · Repligen (RGEN) Q3 2026 earnings results →
Q3 2026 Revenue up 11% year over year to $209M · 18¢ of every $1 of revenue lost · operating margin -14.1%
Repligen made $209M in Q3 2026 (+11% Y/Y): Product $209M, Royalty and other revenue $44K. Operating margin -14.1%, net loss $38.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $209.3M in Q3 2026, up 11% year over year and up 3% from the previous quarter. Product was the largest line at 100% of revenue. Product added $20.5M year over year (up 11%), 100% of the total change.
Operating costs exceeded revenue by $29.5M, an operating margin of -14.1%. Total costs grew 39% against revenue growth of 11%. The quarter ended with a net loss of $38.4M, after a profit of $5.0M the previous quarter.
Operating cash flow was $43.1M (down 10% year over year). Non-cash charges added back $19.1M of depreciation and amortization and $9.4M of share-based compensation. Working capital and other items added $53.1M. Capital expenditures of $4.9M left free cash flow of $38.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $209M | +11% | -14.1% | −$38.4M | $43.1M |
| Q2 2026 | 10-Q | Jul 29, 2026 | $204M | +12% | 6.8% | $5.0M | $32.8M |
| Q1 2026 | 10-Q | May 6, 2026 | $194M | +15% | 8.2% | $8.3M | $28.3M |
| Q4 2025 | 10-K | Feb 26, 2026 | $198M | +18% | 9.0% | $13.3M | $25.7M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $189M | +22% | 8.9% | $14.9M | $48.1M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $182M | +15% | 7.6% | $14.9M | $28.6M |
| Q1 2025 | 10-Q | Apr 29, 2025 | $169M | +10% | 3.9% | $5.8M | $15.0M |
Charts
In supply chains and themes
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Repligen
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
In its own words, from its 8-K, filed Jul 28, 2026.
Repligen against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +11%. Operating margin: -14.1% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RGEN Repligen | Q3 2026 | $209M | +11% | -14.1% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Repligen 10-Q on SEC EDGAR · CIK 730272 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns RGEN and who is buying
More on RGEN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Repligen guidance history: guided vs reported
- Repligen operating margin by quarter
- Repligen net income by quarter
- Repligen free cash flow by quarter
- Repligen R&D spending by quarter
- Repligen capital expenditures by quarter
- Repligen Product revenue by quarter
- Repligen Royalty and other revenue revenue by quarter